FY2023 EPS Estimates for SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Lowered by Analyst

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) – Cantor Fitzgerald decreased their FY2023 earnings per share (EPS) estimates for SELLAS Life Sciences Group in a report released on Monday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($1.04) per share for the year, down from their previous forecast of ($0.76). Cantor Fitzgerald currently has a “Overweight” rating and a $3.00 price objective on the stock. The consensus estimate for SELLAS Life Sciences Group’s current full-year earnings is ($0.86) per share. Cantor Fitzgerald also issued estimates for SELLAS Life Sciences Group’s FY2024 earnings at ($0.78) EPS.

SELLAS Life Sciences Group Price Performance

Shares of SELLAS Life Sciences Group stock opened at $0.92 on Thursday. SELLAS Life Sciences Group has a 1 year low of $0.81 and a 1 year high of $4.13. The business has a 50-day moving average of $1.25 and a two-hundred day moving average of $1.48. The company has a market capitalization of $29.52 million, a P/E ratio of -0.60 and a beta of 2.37.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several large investors have recently modified their holdings of the business. Prosperity Financial Group Inc. bought a new stake in shares of SELLAS Life Sciences Group in the second quarter worth about $47,000. BlackRock Inc. increased its holdings in shares of SELLAS Life Sciences Group by 8.4% in the second quarter. BlackRock Inc. now owns 283,368 shares of the company’s stock worth $445,000 after acquiring an additional 21,885 shares in the last quarter. Northern Trust Corp increased its holdings in shares of SELLAS Life Sciences Group by 31.1% in the second quarter. Northern Trust Corp now owns 39,360 shares of the company’s stock worth $62,000 after acquiring an additional 9,342 shares in the last quarter. State Street Corp grew its holdings in shares of SELLAS Life Sciences Group by 35.4% during the first quarter. State Street Corp now owns 97,129 shares of the company’s stock worth $139,000 after buying an additional 25,400 shares in the last quarter. Finally, Equitable Holdings Inc. grew its holdings in shares of SELLAS Life Sciences Group by 15.0% during the first quarter. Equitable Holdings Inc. now owns 130,000 shares of the company’s stock worth $186,000 after buying an additional 17,000 shares in the last quarter. 10.88% of the stock is currently owned by institutional investors.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.